摘要
目的评估重组人血小板生成素注射液(简称“rhTPO”)对比艾曲泊帕乙醇胺片(简称“艾曲泊帕”)在中国原发免疫性血小板减少症(ITP)成人患者二线治疗中的经济性。方法基于嵌入决策树的马尔可夫模型,以4周为循环周期,从卫生体系角度对患者使用2种药物后的出血事件、不良事件等有关成本和效用进行测算和比较。研究时限为12周,不对成本和健康产出贴现。结果rhTPO较艾曲泊帕提高了0.0025质量调整生命年,并减少了成本1824.36元,为绝对优势方案。单因素敏感性分析结果显示,维持期rhTPO、艾曲泊帕用量对结果的影响较大,但多数情况下rhTPO较艾曲泊帕更具有经济性;概率敏感性分析结果显示,当意愿支付阈值在0~25万元间变动时,rhTPO具有经济性的概率为99.90%~100%。结论在现有证据下,rhTPO相较艾曲泊帕用于二线治疗ITP在短期内更具有经济性。
OBJECTIVE To evaluate the economical efficiency of Recombinant human thrombopoietin injection(called“rhTPO”for short)versus Etrapopa ethanolamine tablets(called“Etrapopa”for short)in the second-line treatment of primary immune thrombocytopenia(ITP)in the Chinese adult patients.METHODS Based on the decision tree-embedded Markov model with a 4-week cycle,the cost and utility related to bleeding events and adverse events after the use of the two drugs were measured and compared from the perspective of Chinese health system.The horizon was 12 weeks,and the cost and health outcome were not discounted.RESULTS Compared with Etrapopa,rhTPO improved the quality adjusted life year by 0.0025 and reduced the cost by 1824.36 yuan,which was the absolute advantage scheme.Univariate sensitivity analysis showed that the base results were greatly affected by the dosage of rhTPO and Etrapopa during maintainance period.In most cases,rhTPO was economical.Probability sensitivity analysis showed that when willingness-to-pay threshold varied between 0 yuan and 250000 yuan,the probability about that rhTPO was economical ranges from 99.90%to 100%.CONCLUSIONS Based on the available evidence,rhTPO is more economical in the short term than Etrapopa in the second-line treatment of ITP.
作者
经天宇
刘海娇
刘朝一
JING Tianyu;LIU Haijiao;LIU Chaoyi(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China)
出处
《中国药房》
CAS
北大核心
2022年第9期1109-1114,共6页
China Pharmacy
